ReviewCancers2018
Rare Genetic Diseases with Defects in DNA Repair: Opportunities and Challenges in Orphan Drug Development for Targeted Cancer Therapy.
Review in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 50 citations in OpenAlex.
- A new wave of innovations within the DNA damage response.Signal transduction and targeted therapy · 2023Review
- PRPF19 modulates morphology and growth behavior in a cell culture model of human skin.Frontiers in aging · 2023Article
- STAT3-induced NCK1 elevation promotes migration of triple-negative breast cancer cells via regulating ERK1/2 signaling.Molecular biology reports · 2022Article
- FZD2 promotes TGF-β-induced epithelial-to-mesenchymal transition in breast cancer via activating notch signaling pathway.Cancer cell international · 2021Article
- Suppression of Tumorigenicity 5 Ameliorates Tumor Characteristics of Invasive Breast Cancer CellsFrontiers in oncology · 2021Article
- Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients.Cancer cell international · 2020Article
- Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.International journal of molecular sciences · 2020Article
- Pterostilbene Sensitizes Cisplatin-Resistant Human Bladder Cancer Cells with OncogenicCancers · 2020Article
- PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective.Oncology letters · 2020Review
- Inhibition of Tyrosyl-DNA Phosphodiesterase 1 by Lipophilic Pyrimidine Nucleosides.Molecules (Basel, Switzerland) · 2020Article
- Aberrant methylation of WD-repeat protein 41 contributes to tumour progression in triple-negative breast cancer.Journal of cellular and molecular medicine · 2020Article
- Hallmarks of Splicing Defects in Cancer: Clinical Applications in the Era of Personalized Medicine.Cancers · 2020Review
- Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2.Cancer medicine · 2020Article
- Combination Therapy with Vitamin C Could Eradicate Cancer Stem Cells.Biomolecules · 2020Review
- MTA2 as a Potential Biomarker and Its Involvement in Metastatic Progression of Human Renal Cancer by miR-133b Targeting MMP-9.Cancers · 2019Article
- Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer.Journal of experimental & clinical cancer research : CR · 2019Article
- Observational
- Smoking index, lifestyle factors, and genomic instability assessed by single-cell gel electrophoresis: a cross-sectional study in subjects from Yucatan, Mexico.Clinical epigenetics · 2019Article
- Review
- RNA-induced initiation of transcriptional silencing (RITS) complex structure and function.RNA biology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A better understanding of mechanistic insights into genes and enzymes implicated in rare diseases provide a unique opportunity for orphan drug development. Advances made in identification of synthetic lethal relationships between rare disorder genes with oncogenes and tumor suppressor genes have brought in new anticancer therapeutic opportunities. Additionally, the rapid development of small molecule inhibitors against enzymes that participate in DNA damage response and repair has been a successful strategy for targeted cancer therapeutics. Here, we discuss the recent advances in our understanding of how many rare disease genes participate in promoting genome stability. We also summarize the latest developments in exploiting rare diseases to uncover new biological mechanisms and identify new synthetic lethal interactions for anticancer drug discovery that are in various stages of preclinical and clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.